120 related articles for article (PubMed ID: 31781480)
1. Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors.
Herath NI; Berthault N; Thierry S; Jdey W; Lienafa MC; Bono F; Noguiez-Hellin P; Sun JS; Dutreix M
Front Oncol; 2019; 9():1097. PubMed ID: 31781480
[No Abstract] [Full Text] [Related]
2. AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance.
Jdey W; Kozlak M; Alekseev S; Thierry S; Lascaux P; Girard PM; Bono F; Dutreix M
Neoplasia; 2019 Sep; 21(9):863-871. PubMed ID: 31362243
[TBL] [Abstract][Full Text] [Related]
3. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
4. The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood.
Thierry S; Jdey W; Alculumbre S; Soumelis V; Noguiez-Hellin P; Dutreix M
Mol Cancer Ther; 2017 Dec; 16(12):2817-2827. PubMed ID: 28947503
[TBL] [Abstract][Full Text] [Related]
5. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA Repair by Inappropriate Activation of ATM, PARP, and DNA-PK with the Drug Agonist AsiDNA.
Berthault N; Bergam P; Pereira F; Girard PM; Dutreix M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883597
[TBL] [Abstract][Full Text] [Related]
7. AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models.
Ferreira S; Foray C; Gatto A; Larcher M; Heinrich S; Lupu M; Mispelter J; Boussin FD; Pouponnot C; Dutreix M
Clin Cancer Res; 2020 Nov; 26(21):5735-5746. PubMed ID: 32900798
[TBL] [Abstract][Full Text] [Related]
8. Effect of DNA repair inhibitor AsiDNA on the incidence of telomere fusion in crisis.
Subecz C; Sun JS; Roger L
Hum Mol Genet; 2021 Apr; 30(3-4):172-181. PubMed ID: 33480989
[TBL] [Abstract][Full Text] [Related]
9. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
10. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
Lee JM; Peer CJ; Yu M; Amable L; Gordon N; Annunziata CM; Houston N; Goey AK; Sissung TM; Parker B; Minasian L; Chiou VL; Murphy RF; Widemann BC; Figg WD; Kohn EC
Clin Cancer Res; 2017 Mar; 23(6):1397-1406. PubMed ID: 27663600
[No Abstract] [Full Text] [Related]
11. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
Novohradsky V; Zajac J; Vrana O; Kasparkova J; Brabec V
Oncotarget; 2018 Jun; 9(47):28456-28473. PubMed ID: 29983873
[TBL] [Abstract][Full Text] [Related]
13. Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
Lampert EJ; Hays JL; Kohn EC; Annunziata CM; Minasian L; Yu M; Gordon N; Sissung TM; Chiou VL; Figg WD; Houston N; Lee JM
Oncotarget; 2019 Apr; 10(30):2855-2868. PubMed ID: 31080557
[No Abstract] [Full Text] [Related]
14. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
15. Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal, and higher sensitivity to the drug.
Girard PM; Berthault N; Kozlac M; Ferreira S; Jdey W; Bhaskara S; Alekseev S; Thomas F; Dutreix M
Evol Appl; 2020 Aug; 13(7):1673-1680. PubMed ID: 32821277
[TBL] [Abstract][Full Text] [Related]
16. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
18. Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA.
Jdey W; Thierry S; Popova T; Stern MH; Dutreix M
Cancer Res; 2017 Aug; 77(16):4207-4216. PubMed ID: 28588010
[TBL] [Abstract][Full Text] [Related]
19. STL127705 synergize with olaparib in castration-resistant prostate cancer by inhibiting homologous recombination and non-homologous end-joining repair.
Sun P; Zhao W; Li H; Feng Y; Chen L; Cao H
Am J Cancer Res; 2023; 13(5):2030-2040. PubMed ID: 37293174
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells.
Zhao H; Yang Q; Hu Y; Zhang J
Oncol Rep; 2018 Dec; 40(6):3223-3234. PubMed ID: 30272286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
